Drug Profile


Alternative Names: DCC-2036; DP-1919; DP-1919.TO

Latest Information Update: 24 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Albert Einstein College of Medicine; Deciphera Pharmaceuticals
  • Class Antineoplastics; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors; Proto-oncogene protein c-hck inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Phase I Breast cancer

Most Recent Events

  • 19 Jul 2016 Deciphera Pharmaceuticals and Montefiore Medical Center plan a phase I trial in Breast cancer (Late-stage disease; Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02824575)
  • 01 Jul 2016 Phase-I clinical trials in Breast cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02824575)
  • 22 Sep 2015 Phase-I/II development for Leukaemia (Acute lymphoblastic leukaemia, chronic myeloid leukaemia and acute myeloid leukaemia) completed in USA and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top